You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Ebglyss ™ (lebrikizumab-lbkz) injection
250 mg/2 mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the dosing of Ebglyss® (lebrikizumab-lbkz) for atopic dermatitis?
The recommended dosage of lebrikizumab in adults and adolescents is a loading dose of 500 mg at week 0 and 2, followed by 250 mg every 2 weeks until week 16 or when adequate clinical response is achieved. The maintenance dose is 250 mg every 4 or 8 weeks.
Prescribing Information
Ebglyss® (lebrikizumab-lbkz) is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab-lbkz can be used with or without topical corticosteroids (TCS).1
Description
Lebrikizumab-lbkz injection is a sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous use. Lebrikizumab-lbkz is available as either a 250 mg/2 mL single-dose prefilled pen or a single-dose prefilled syringe with needle shield. The lebrikizumab-lbkz prefilled pen and prefilled syringe with needle shield are not made with natural rubber latex.1
Each prefilled pen or prefilled syringe delivers 250 mg lebrikizumab-lbkz in 2 mL solution which also contains glacial acetic acid (1.8 mg), histidine (6.2 mg), polysorbate 20 (0.6 mg), sucrose (119.6 mg) and Water for Injection. The pH is 5.4 – 6.0.1
Recommended Dosage
The recommended subcutaneous dosage of lebrikizumab-lbkz is an initial dose of 500 mg (two 250 mg injections) at week 0 and week 2, followed by 250 mg (one injection) every 2 weeks until week 16 or later, when adequate clinical response is achieved. The maintenance dose of lebrikizumab-lbkz is 250 mg every 4 weeks or 250 mg every 8 weeks.1
Concomitant Topical Therapies
Lebrikizumab-lbkz can be used with or without TCS. Topical calcineurin inhibitors may be used, but reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas.1
Missed Dose
If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.1
Overdosage
There is no specific treatment for lebrikizumab-lbkz overdose. Single intravenous doses up to 10 mg/kg and multiple subcutaneous doses up to 500 mg have been administered to humans in clinical trials without dose-limiting toxicity.2 In the event of overdosage, contact Poison Control (1-800-222-1222) for the latest recommendations. Monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.1
Enclosed Prescribing Information
Reference
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Ebglyss [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: June 09, 2026